Aptinyx Current Ratio 2017-2021 | APTX

Aptinyx current ratio from 2017 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Aptinyx Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.13B $0.00B 39.56
2021-03-31 $0.15B $0.00B 39.30
2020-12-31 $0.15B $0.01B 32.64
2020-09-30 $0.11B $0.00B 26.50
2020-06-30 $0.12B $0.00B 30.70
2020-03-31 $0.13B $0.01B 27.15
2019-12-31 $0.11B $0.01B 21.47
2019-09-30 $0.12B $0.01B 16.75
2019-06-30 $0.13B $0.01B 26.89
2019-03-31 $0.14B $0.01B 23.43
2018-12-31 $0.15B $0.01B 26.04
2018-09-30 $0.17B $0.01B 21.84
2018-06-30 $0.18B $0.01B 24.08
2018-03-31 $0.00B 0.00
2017-12-31 $0.00B 0.00
2017-09-30 $0.00B 0.00
2017-06-30 $0.00B 0.00
2016-12-31 $0.02B $0.01B 3.80
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.150B $0.002B
Aptinyx Inc. is a bio-pharmaceutical company. It focuses on discovery, development, and commercialization of novel, proprietary and synthetic small molecules for the treatment of brain and nervous system disorders. The company's product pipeline consists of NYX-2925, NYX-783 and NYX-458 which are in clinical stage. Aptinyx Inc. is based in IL, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76